Anthony @ Equity Investigations, Dear Anthony, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony,

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony@Pacific who wrote (12802)	2/20/1999 11:15:00 AM
From: StockHawk	Read Replies (1) of 122087

Anthony, Do you think IMNX might be a possible short candidate here? The stock ran from about $50 last Oct. to $150 recently based on approval of Enbrel, a treatment for rheumatoid arthritis (RA). There are great expectations for the success of this drug, however, it may not be as successful as anticipated. While there are many treatments for RA, there is no cure and patients tend to try every new drug that comes out. Enbrel was approved only for use by advanced patients who have failed other remedies. It requires injections. Monsanto just come out with Celebrex, a pill approved for treatment of RA that is marketed by Pfizer. Merck should have a new pill approved for RA this summer. With this new competition and patient's tendencies to move from one new product to the next, IMNX could hit hard if sales fall off. The stock has been volatile recently in a range of approximately $130 to $150.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next